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Edited by Horst FeldmannAbstract RNA protection experiments and the crystal structure
of a complex of the large ribosomal subunit from the eubacte-
rium Deinococcus radiodurans with rapamycin, a polyketide
compound resembling macrolides and ketolides, showed that rap-
amycin binds to a crevice located at the boundaries of the nascent
protein exit tunnel, near its entrance. At this location rapamycin
cannot occlude the ribosome exit tunnel, consistent with its fail-
ure to act as a ribosomal antibiotic drug. In accord with recent
biochemical data, this crevice may play a role in facilitating local
cotranslational folding of nascent chains, in particular for trans-
membrane proteins.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Nascent proteins emerge out of the ribosome through an exit
tunnel, a universal feature of the large ribosomal subunit. The
entrance to this tunnel is adjacent to the peptidyl transferase
center (PTC), and its opening is located at the other end of
the subunit. High-resolution crystal structures showed that
the tunnel is rather kinked, has a non-uniform diameter, and
contains grooves and cavities [1,2]. Originally, this tunnel
was assumed to be a ﬁrmly built passive path [1] that does
not interact with the nascent proteins and is not involved in
their progression. However, biochemical results, accumulated
during last decade, indicate that the tunnel plays an active role
in sequence-speciﬁc gating of nascent chains (reviewed in [3–8])
and in responding to cellular signals. Indeed, crystal structures
of complexes of the large ribosomal subunit from the eubacte-
rium Deinococcus radiodurans indicated that the tunnel has the
capability to oscillate between conformations, and that these
alterations could be correlated with nascent protein sequence
discrimination and gating [9], as well as with its traﬃcking into
its chaperone-folding cradle [10].
At its entrance the tunnel diameter may limit the passage of
folded polypeptides. Furthermore, in speciﬁc cases, likely be*Corresponding author.
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doi:10.1016/j.febslet.2005.03.023connected with nascent-chain-tunnel interactions, it may ham-
per the progression of protein sequences known to arrest elon-
gation [11,12]. The rotatory motion that translocates the
aminoacylated A-site tRNA 3 0 end into the P-site while pep-
tide bond is being formed [13] dictates that the side chains of
successive residues are pointing to opposite sides. Hence,nas-
cent proteins enter into the tunnel at an extended conforma-
tion, which complies well with the tunnel narrow entrance as
well as with the suggestion that motions of rigid residues, such
as prolines, may be restricted under speciﬁc cellular conditions
[10,14].
So far most of the tunnel functional roles have been attrib-
uted to mobile extended loops of ribosomal proteins that pen-
etrate its walls, which are primarily made of ribosomal RNA.
Examples are the tips of extended loops of proteins L22 and
L23. Thus, the beta-hairpin tip of L22 that can swing across
the tunnel around its accurately placed hinge, appears to pro-
vide the mechanism for elongation arrest when triggered by
speciﬁc cellular conditions [9,15]. Similarly, the tip of L23
internal loop undergoes allosteric conformational changes that
can modulate the shape and the size of the tunnel opening
upon binding the trigger factor, the ﬁrst chaperone encounter-
ing the emerging nascent chain in eubacteria [10]. Both can
provide communication routes for signaling between the ribo-
some and the cell, as their other ends are located on the solvent
side of the ribosome, in the proximity of the tunnel opening
[9,15].
The protein exit tunnel is the target of macrolide antibiotics,
which rank highest in clinical usage and act by producing a ste-
ric blockage of the ribosome exit tunnel, hence hampering the
progression of nascent chains [9,16–19]. These natural and
semi-synthetic compounds are characterized by a macrolac-
tone ring to which at least one sugar moiety is attached (Fig.
1). Ketolides belong to a novel class of the macrolide family,
characterized by a keto group at position 3 of the macrolac-
tone ring, a single amino-sugar moiety and an extended hydro-
phobic arm. This recently developed drug family was designed
to act against several macrolide resistant bacterial strains.
High-resolution crystal structures of complexes of macrolides
and ketolides with D50S [16–18], an excellent pathogen model
for these studies, showed that they bind to a speciﬁc pocket in
the eubacterial tunnel, called below the macrolide binding-
pocket. These crystallographically observed macrolide interac-
tions illuminated resistance mechanisms involving rRNA
modiﬁcation. Alterations in the tunnel conformation seen crys-
tallographically [9], and the structural analysis of the nature
of the dynamic tunnel constriction, built of the tips of
extended loops of L22 and L4 [20], could be correlated withblished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structures of rapamycin, erythromycin, telithromycin and ABT-773.
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teins [10,21–23].
Rapamycin, a compound isolated from a strain of Strepto-
myces hygroscopicus, resembles to some extent, the molecular
structures of antibiotics from the macrolide/ ketolide family,
sharing with them a rather hydrophobic lipophilic ring, but
lacking the sugar moieties [24,25] (Fig. 1). This polyketide
serves as an immunosuppressive agent and has a strong impact
on the control of biosynthesis in both unicellular and multi-cel-
lular eukaryotes. Once bound to its receptor, the immunophi-
lin FKBP, rapamycin targets the evolutionarily conserved
TOR (target of rapamycin) proteins, which are eﬀectors for
signals indicating to the cell whether the external conditions
are adequate for growth in both unicellular and multi-cellular
organisms [26]. It was also shown that TOR controls 35S and
5S rRNA synthesis via RNA polymerase I and polymerase III,
respectively [27,28], and ribosomal proteins gene expression
via the transcription factor FHL1 [29]. Rapamycin treatment
mimics nutrient deprivation. Consequently, ribosome produc-
tion is curtailed through TOR functions, or a cell may even be-
gin to degrade ribosomes, in a process called autophagy. In
addition, rapamycin causes substantial changes in the cellular
transcriptome and reduces protein synthesis by targeting the
initiation step of translation [30]. A similar signaling mecha-
nism does not exist in bacteria, where biosynthesis is directly
controlled by aminoacid and ATP abundance [31,32].
Given its structure similarity to macrolides, we assumed that
rapamycin might bind to the tunnel of eubacterial ribosomes
and shed light on the tunnel binding capabilities, although isnot known as a powerful ribosomal antibiotic. We therefore
conducted crystallographic analysis of rapamycin complexed
with the large ribosomal subunit of D. radiodurans (D50S)
and veriﬁed our results by RNA probing. Here, we show that
rapamycin binds to a crevice, built exclusively of 23S RNA
nucleotides, located at the tunnel wall opposite to the macro-
lide-binding site. These ﬁndings conﬁrm that the tunnel pos-
sesses speciﬁc binding properties. We suggest that the
identiﬁed binding crevice in the tunnel plays a role in nascent
protein progression, despite the initial description of the tunnel
as a ‘‘non-sticky’’ path [1].2. Materials and methods
2.1. Base numbering
Nucleotides are numbered according to Escherichia coli numbering,
unless speciﬁed by DR for D. radiodurans.
2.2. Crystallization, data collection and processing
Co-crystals of D50S with 0.01 mM rapamycin were grown using the
hanging drop method, as in [2]. Data were collected at 90–100 K at
ID29/ESRF/EMBL and ID19/APS/ANL, and recorded on Quan-
tum-210 and APS detectors, respectively. Data were processed and
scaled with the DENZO/SCALEPACK/HKL2000 package [33] and
their statistics are shown in Table 1.
2.3. Rapamycin placement and structure reﬁnement
Overall and group rigid body reﬁnements were performed with CNS
[34] using the 3.0 A˚ resolution structure of D50S as a starting model
[2]. SigmaA-weighted (Fo  Fc) and (2Fo  Fc) maps indicated signiﬁ-
Table 1
Crystallographic data
Space group I222
Wavelength (A˚) 0.939
Unit cell parameters (A˚) 168.5, 404.0, 689.0
Resolution range (A˚) 20-3.8
Mosaicity () 0.3
Number of unique reﬂections 191012
Completeness (%) 82.8 (75.0)
Rmerge (%) 16 (56)
ÆIæ/Ær(I)æ 6.1 (1.6)
Redundancy 2.1
R-factor/R-free (%) 27.3/36.8 (5%)
r.m.s. deviations from ideality
Bond lengths (A˚) 0.003
Bond angles () 0.61
Values in parentheses refer to the highest resolution shell (A˚).
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rapamycin and of the nucleotides involved in its binding were modeled
interactively using the graphics model building program O [35]. Posi-
tional and residue temperature factors reﬁnements of the obtained
model were alternated with rounds of model building. The free-R fac-
tor, computed using 5% of the data, was used to monitor the reﬁne-
ment (Table 1). The structure exhibits good stereochemistry, as
analyzed by Procheck [36]. Modeling of a nascent chain in the exit tun-
nel was carried out with O [35]. The percentage of accessible surface
(AS) upon binding was calculated, using the CCP4 package [36], as
the diﬀerence between the AS of an isolated rapamycin and that of a
bound one, divided by the AS of an isolated rapamycin. Coordinates
have been deposited in the protein data bank (accession code 1Z58).
The structural ﬁgures were produced with RIBBONS [37].
2.4. RNA probing by footprinting experiments
(a) Antibiotic binding to ribosomal particles. One A260 unit (36 pmol)
of D50S subunit of the ribosome was incubated at 37 C for 30 min
with rapamycin (Sigma) at concentrations ranging from 1 to 100 lM
in a buﬀer containing 10 mM HEPES, 10 mM MgCl2, and 60 mM
NH4Cl, in sterile microcentrifuge tubes.
(b) Footprinting. Following antibiotic binding, the ribosomes were
incubated at 42 C for 10 min and on ice for additional 10 min, in
DMS modiﬁcation buﬀer. The DMS modiﬁcation was carried out on
ice, essentially as described in [38]. Primer extension was preformed
using several DNA primers designed to complement 23S rRNA re-
gions located at the vicinity of the crystallographically determined
macrolide binding pocket and rapamycin binding region, including
GCCGATATGGACTC, aimed at modiﬁcations of for A2418DR
(2439EC) and C2419DR (2440EC).3. Results and discussion
3.1. Rapamycin binding site
The crystal structure of D50S co-crystallized with rapamycin
shows clearly (Fig. 2A) that rapamycin binds to a crevice lo-
cated at the tunnel wall, in the vicinity of the macrolide-bind-
ing pocket and the dynamic tunnel-constriction, and that
rapamycin interacts with RNA nucleotides of domains V, II
and IV (Fig. 2B). It also indicates that rapamycin interacts so-
lely with the 23S RNA (Fig. 2C) via hydrophobic interactions
and hydrogen bonds, and about 60% of its surface area is bur-
ied upon binding. The crystallographically determined binding
site was veriﬁed by chemical RNA probing.
Rapamycin binding crevice is located closer to the PTC than
the macrolide-binding pocket. The locations of the centers of
mass of erythromycin and rapamycin in the ribosome tunnel
are separated by about 11 A˚ away from each other. Hence,
nascent proteins, progressing through the tunnel, will pass near
the rapamycin-binding crevice before reaching the macrolide-binding pocket and the dynamic tunnel constriction (Fig. 3A
and B). Importantly, rapamycin-binding fashion is dramati-
cally diﬀerent from that of macrolides and ketolides (Figs.
2C and 3B and C). Nevertheless, some of rapamycin interac-
tions with domain V, such as those with nucleotides C2586,
A2587 and U2609, are typical of macrolides, whereas no con-
tacts are observed with 2058, the 23S RNA nucleotide that
provides the primary macrolide binding interactions and is in-
volved in macrolide selectivity and resistance (for review see
[40]). In accord with the rapamycin crystallographic position-
ing, rapamycin binding signiﬁcantly modiﬁes the accessibility
of nucleotides C2440 (C2419DR) and A2439 (A2418DR) to
chemical probing (Fig. 2), indicating that these two nucleotides
are protected by rapamycin. The major decrease in accessibil-
ity (75%) was observed for C2440 (C2419DR), consistent
with the proximity (4 A˚) of its ribose O2 0 to the O3 of rapa-
mycin. Even A2439 (A2418DR), which is not directly involved
in rapamycin binding, but is partially masked by rapamycin,
showed about 40% decrease in accessibility to DMS.
On the other hand, rapamycin-binding site partially overlaps
with the location of the far end of the ketolides telithromycin
[16] and ABT-773 [17] (Fig. 3C). In particular, drug interac-
tions involving the nucleotide U790 (C803DR), belonging to
helix H35 of domain II of the 23S RNA (Fig. 2B), were ob-
served also for the extended arms of telithromycin [16] and
ABT-773 (Fig. 1) [17]. Similarly, contacts with the domain
IV nucleotide U1782 (C1773DR) (Fig. 2B) have been sug-
gested to stabilize ABT-773 binding [17].
Altogether, these ﬁndings indicate that the crevice formed by
domain II nucleotides U790 (C803DR) and A752 (C765DR)
and domain IV nucleotides C1781 and U1782 (C1772DR
and C1773DR) has a high potential for the binding of rapamy-
cin-like compounds. Therefore, this crevice provides an alter-
native anchoring point for compounds that cannot interact
with the nucleotide at position 2058 (2041DR) because of resis-
tance-induced modiﬁcations or the absence of a desosamine
sugar. This is consistent with the proposal that the interactions
with such binding crevice provide additional binding capabili-
ties to ketolides, even when A2058 (A2041DR) is methylated
or mutated [16,17,41].3.2. Functional implications
The existence of a crevice that has the ability to provide a
speciﬁc binding site suggests that it may play a role in ribo-
some function. This crevice is of a size suitable for accommo-
dating small secondary structural elements, and therefore may
provide the newly born protein with a site for adopting a par-
ticular fold at the early stage of tunnel passage. This is consis-
tent with a large range of biochemical evidence, obtained
mainly for transmembrane proteins, implicating cotransla-
tional folding [3–8]. Transmembrane segments are, similar to
rapamycin, highly hydrophobic, and therefore may be accom-
modated within the crevice. Hence, the identiﬁed crevice may
provide the space as well as a proper hydrophobic patch that
might act as an inner-tunnel chaperone, consistent with ﬁnd-
ings interpreted as nascent chain folding near the PTC, which
was proposed to correlate with sequential closing and opening
of the translocon at the ER membrane [42].
Cotranslational folding is frequently observed for eukaryotic
membrane proteins. It is conceivable that the eukaryotic ribo-
some possesses a comparable crevice, as a similar feature could
Fig. 2. (A) A stereo view of rapamycin omit (Fo  Fc) electron-density-map. (B) The two-dimensional representation of the 23S rRNA nucleotides
involved in macrolide binding. Translation code from E. coli to D. radiodurans is also shown. (C) A stereo view of 23S RNA nucleotides interacting
with rapamycin (cyan). For comparison, the 23S RNA nucleotides interacting with erythromycin are shown in blue. Note the diﬀerences in the
conformations of nucleotides A2602 and U2609, induced by rapamycin binding.
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postulate the existence of a crevice in ribosomes from all king-
doms of life, we do not imply structural identity. Thus, phylo-
genetic diversity should play a considerable role in its detailed
structure, as found at the macrolide-binding pocket [10,20,43].
Hence, the binding aﬃnities of this crevice may vary, explain-
ing why rapamycin is not known to strongly inhibit membrane
proteins translation.
The cotranslational folding may be only transient, until mes-
sages are transmitted to other cell components (e.g., the tran-slocone pore [7,42]). Alternatively, it is conceivable that once
small nucleation centers are formed, they may progress
through the tunnel by temporary expansions of the tunnel-
diameter, as observed recently for translation-arrested ribo-
somes [44]. Thus, our provisional assignment of the crevice
functional role can be integrated into our previous ﬁndings
concerning the tunnel dynamic properties that enable its par-
ticipation in polypeptide elongation and arrest, sequence dis-
crimination and signaling to various cellular components,
including the ER membrane.
Fig. 3. (A) The positions of rapamycin crevice, C, in relation to the macrolide-binding site, m, and the tunnel constriction composed of the tips of the
elongated loops of proteins L4 and L22. The large ribosomal subunit form D. radiodurans [2], sectioned so that the internal exit tunnel can be seen, is
shown in transparent gray. Also shown are the A- and P-site tRNAs, docked on the large subunit using the structure of the entire ribosome complex
[39] and a modeled nascent chain [9]. (B) A more detailed view of the ribosomal components around rapamycin binding site. Erythromycin binding
site is also shown, for comparison. (C) Superposition of the locations of rapamycin, erythromycin, telithromycin and ABT-773 in D50S.
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tra-ribosome chaperon does not provide suﬃcient structural
tools for answering fundamental questions such as: do nas-
cent chains retain a single or acquire multi-conformations
while traveling through the tunnel? Is there a signaling mech-
anism dictating the nascent chain conformation and initiat-
ing local folding? Does the tunnel normally switch between
open and constricted conformations? What is the conforma-
tional state of nascent chains when they emerge out of the
exit tunnel?
3.2.1. Medical implications. The binding mode observed
for rapamycin suggested that anchoring to the tunnel is only
a prerequisite for the polyketide antibiotic function. Indeed,
rapamycin binding crevice is located aside the typical macro-
lide-binding pocket (Figs. 1C and 3B and C). Furthermore,
by modeling a nascent chain in the exit tunnel, we show that,
diﬀerent from macrolides and ketolides studied so far, rapamy-
cin-binding mode leaves suﬃcient tunnel space for the nascent
chain (Fig. 3B and C). Our present results are therefore consis-
tent with previous observations that a necessary requirement
for eﬃcient antibiotic activity of macrolide-like compounds
is their binding to the ribosome exit tunnel, in a manner that
eﬃciently blocks the tunnel. So far, we found that this mode
of binding is conferred to macrolides and ketolides by their
desosamine sugars [9,16–18]. Rapamycin binding to eubacte-
rial ribosomes may be exploited for designing improved
antibiotics.
A2058 is the primary macrolide-binding nucleotide, via its
desosamine sugar [18] and is implicated in macrolide resistance
and selectivity via mechanisms based on modiﬁcations of its
base, either by di-methylation by Erm methylases or by muta-
tion to guanine, the nucleotide commonly found at this posi-
tion in eukaryotes and archaea [40]. Since rapamycin binding
does not involve the nucleotide at position 2058, it appears
that erythromycin and MLS resistance-inducing mutations
would not aﬀect rapamycin binding. Furthermore, as the des-
osamine sugar of macrolides and ketolides plays an important
role in their binding, the study of the binding interactions of a
molecule resembling macrolides, albeit lacking a desosaminesugar, should lead to the identiﬁcation of novel binding
patches of the ribosome exit tunnel for which no resistance
has yet been developed by bacterial strains.
Rapamycin central ring is signiﬁcantly larger than those of
macrolides, which consist typically of 14–16 atoms. It was
found that the ﬂexibility of this ring increases as a function
of its size, resulting in the binding of macrolides with 15 or
16-memebered rings to ribosomes having G in position 2058,
such as H50S, which do not bind typical macrolides at all
[45]. Similarly, it is likely that the increased ﬂexibility of rapa-
mycin central ring could be used for designing new antibiotics.
Finally, despite the partial overlap between rapamycin and the
macrolide and ketolide binding sites, no cross-reactivity was
observed between these compounds (M. Amit, unpublished
data). Hence, a careful comparison between the eﬀective and
non-eﬀective modes of binding, namely between the telithro-
mycin, ABT-773 (cethromycin) and rapamycin, can identify
the minimal requirements for therapeutic eﬀectiveness.4. Conclusions
Analysis of the crystal structure of D50S in complex with
rapamycin showed that rapamycin binds to the ribosome exit
tunnel in a crevice located aside the typical macrolide-binding
pocket. Our structural results constitute the ﬁrst example of a
non-inactivating binding to the ribosome, thus suggesting that
binding to the tunnel is not suﬃcient to guarantee biosynthesis
inactivation. Thus, we identiﬁed a crevice at the walls of the
exit tunnel that may play a functional role in cotranslational
folding and ribosome-cell signaling, as a non-ribosomal com-
pound binds to it in a speciﬁc way.
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